Top entities: Alnylam Pharmaceuticals, The Law Offices of Frank R. Cruz.

What category does this event fall under?

Regulatory — classified as Securities Investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Alnylam Pharmaceuticals lowered guidance · The Law Offices of Frank R. Cruz launched investigation Alnylam Pharmaceuticals

Is this event still developing?

This is an active story, last updated Aug 12, 2026. Coverage continues to evolve.

Regulatory Securities Investigation

Alnylam Securities Fraud Investigation

Q: When did this event occur?

First reported Jul 30, 2026; last updated Aug 12, 2026.

Q: What is the market impact?

General. The guidance cut and subsequent stock drop have negatively impacted Alnylam's market valuation and investor confidence.

Analysis based on 6 articles · First reported Jul 30, 2026 · Last updated Aug 12, 2026

Sentiment

-60

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The guidance cut and subsequent stock drop have negatively impacted Alnylam's market valuation and investor confidence. The securities investigation adds legal and reputational risk, potentially further pressuring the stock and increasing volatility.

Pharmaceuticals Legal Services

Event Summary

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced on July 30, 2026, that it lowered its full-year 2026 TTR product sales guidance by approximately $200 million, citing learnings from the initial launch phase in the ATTR-CM market and normalization of second-line volume after pent-up demand. Following this announcement, Alnylam's share price fell as much as $81.25, or 28.35%, in intraday trading. The The Law Offices of Frank R. Cruz has launched an investigation into potential violations of federal securities laws by Alnylam, on behalf of investors who lost money. The investigation is ongoing, and the law firm is urging affected shareholders to contact them.

Key Actions

100 Alnylam Pharmaceuticals lowered guidance

70 The Law Offices of Frank R. Cruz launched investigation Alnylam Pharmaceuticals

Entities Involved

stock

Alnylam Pharmaceuticals

Alnylam lowered its 2026 TTR product sales guidance by about $200 million, causing its stock to drop 28.35% intraday. The company now faces a securities fraud investigation, adding legal and reputational risk.

Importance 100.0 Sentiment -70.0

priv

The Law Offices of Frank R. Cruz

The law firm launched an investigation into Alnylam for potential securities law violations, representing investors who lost money. This action could lead to litigation and potential recoveries for shareholders.

Importance 60.0 Sentiment 20.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard